TWST FINANCIAL STATEMENTS

Twist Bioscience Corp — balance sheet, income statement and cash flow trends

TWSTTwist Bioscience Corp

🇺🇸 USA · NASDAQ · Healthcare · Diagnostics & Research

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue409.5 M $+17.8%

Gross Profit213.2 M $+31.3%

Operating Income-138.8 M $—

EBITDA-56.3 M $—

Net Income-81.3 M $—

Peer Comparison· Diagnostics & Research

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
TWST	17.8%	52.1%	-13.8%	-19.8%
SHL	11.4%	29.6%	17.3%	5.2%
ERF	5.0%	12.3%	19.9%	6.5%
Industry median	9.1%	53.0%	18.8%	6.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
TWST	17.8%	52.1%	-13.8%	-19.8%
RDNT	14.7%	9.4%	15.1%	-0.7%
SHC	7.4%	55.0%	41.1%	9.9%
VCYT	16.9%	71.3%	20.7%	16.2%
QGEN	4.8%	61.6%	37.1%	19.2%
CRL	0.1%	31.9%	7.2%	-4.6%
Industry median	9.1%	53.0%	18.8%	6.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity455.1 M $67%
Current Liabilities120 M $18%
Long-term Liabilities101.1 M $15%

Key Figures

YoY change

Total Assets676.2 M $+13.5%

Total Liabilities221.1 M $+42.2%

Total Equity455.1 M $+3.4%

Cash & ST Investments171.7 M $-33.2%

Total Debt95.8 M $+19.4%

Net Debt-26.8 M $—

Peer Comparison· Diagnostics & Research

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
TWST	2.70	21.1%	1.35	67.3%
SHL	1.01	85.8%	3.78	50.3%
ERF	1.09	153.3%	3.20	32.3%
Industry median	1.87	49.3%	1.92	50.1%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
TWST	2.70	21.1%	1.35	67.3%
RDNT	1.17	179.0%	4.56	27.8%
SHC	2.82	364.7%	4.00	19.2%
VCYT	9.31	2.9%	-3.56	93.6%
QGEN	3.21	49.4%	1.29	57.6%
CRL	1.36	103.9%	9.86	38.0%
Industry median	1.87	49.3%	1.92	50.1%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow-55.6 M $—

Capital Expenditures39.6 M $+321.7%

Free Cash Flow-95.1 M $—

Dividends Paid——

Peer Comparison· Diagnostics & Research

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
TWST	-13.6%	-23.2%	9.7%	68.4%
SHL	13.1%	8.3%	4.7%	251.9%
ERF	17.7%	7.3%	10.4%	272.6%
Industry median	16.3%	9.7%	4.5%	110.1%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
TWST	-13.6%	-23.2%	9.7%	68.4%
RDNT	16.3%	-6.9%	23.2%	-2,463.4%
SHC	22.0%	8.1%	13.8%	221.7%
VCYT	30.7%	28.6%	2.1%	188.8%
QGEN	29.3%	19.6%	9.8%	153.0%
CRL	15.1%	9.7%	5.4%	-328.7%
Industry median	16.3%	9.7%	4.5%	110.1%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on TWST

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.